Compare SBGI & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBGI | ERAS |
|---|---|---|
| Founded | 1986 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2023 | 2021 |
| Metric | SBGI | ERAS |
|---|---|---|
| Price | $15.53 | $15.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $21.80 | $7.20 |
| AVG Volume (30 Days) | 398.7K | ★ 3.4M |
| Earning Date | 05-26-2026 | 01-01-0001 |
| Dividend Yield | ★ 6.46% | N/A |
| EPS Growth | N/A | ★ 16.87 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,169,000,000.00 | N/A |
| Revenue This Year | $12.59 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.89 | $1.01 |
| 52 Week High | $17.88 | $16.00 |
| Indicator | SBGI | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 55.79 | 75.80 |
| Support Level | $14.43 | $1.46 |
| Resistance Level | $15.62 | N/A |
| Average True Range (ATR) | 0.76 | 0.86 |
| MACD | 0.10 | 0.05 |
| Stochastic Oscillator | 57.46 | 81.55 |
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.